

Data processing choices can affect findings in differential methylation analyses: an investigation using data from the LIMIT RCT

Jennie Louise^{Corresp., 1, 2}, Andrea R Deussen³, Jodie M Dodd^{3, 4}

¹ Discipline of Obstetrics & Gynaecology and The Robinson Research Institute, The University of Adelaide, Adelaide, Australia

² Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, Australia

³ Discipline of Obstetrics & Gynaecology and The Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia

⁴ Department of Perinatal Medicine, Women's and Babies Division, The Women's and Children's Hospital, Adelaide, South Australia, Australia

Corresponding Author: Jennie Louise

Email address: jennie.louise@adelaide.edu.au

Objective: A wide array of methods exist for processing and analysing DNA methylation data. We aimed to perform a systematic comparison of the behaviour of these methods, using cord blood DNAm from the LIMIT RCT, in relation to detecting hypothesised effects of interest (intervention and pre-pregnancy maternal BMI) as well as effects known to be spurious, and known to be present. **Methods:** DNAm data, from 645 cord blood samples analysed using Illumina 450K BeadChip arrays, were normalised using three different methods (with probe filtering undertaken pre- or post- normalisation). Batch effects were handled with a supervised algorithm, an unsupervised algorithm, or adjustment in the analysis model. Analysis was undertaken with and without adjustment for estimated cell type proportions. The effects estimated included intervention and BMI (effects of interest in the original study), infant sex and randomly assigned groups. Data processing and analysis methods were compared in relation to number and identity of differentially methylated probes, rankings of probes by p value and log-fold-change, and distributions of p values and log-fold-change estimates. **Results:** There were differences corresponding to each of the processing and analysis choices. Importantly, some combinations of data processing choices resulted in a substantial number of spurious 'significant' findings. We recommend greater emphasis on replication and greater use of sensitivity analyses.

Data Processing Choices Can Affect Findings in Differential Methylation Analyses: An Investigation Using Data from the LIMIT RCT

Authors

Jennie Louise^{1,2}
Andrea R Deussen¹
Jodie M Dodd^{1,3}

Affiliations

1. Discipline of Obstetrics & Gynaecology and The Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, AUSTRALIA
2. Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, AUSTRALIA
3. Department of Perinatal Medicine, Women's and Babies Division, The Women's and Children's Hospital, Adelaide, South Australia, AUSTRALIA.

Corresponding Author

Dr Jennie Louise
The University of Adelaide
Women's and Children's Hospital
72 King William Rd
North Adelaide, South Australia, AUSTRALIA 5006
Email: jennie.louise@adelaide.edu.au

Abstract

Objective: A wide array of methods exist for processing and analysing DNA methylation data. We aimed to perform a systematic comparison of the behaviour of these methods, using cord blood DNAm from the LIMIT RCT, in relation to detecting hypothesised effects of interest (intervention and pre-pregnancy maternal BMI) as well as effects known to be spurious, and known to be present.

Methods: DNAm data, from 645 cord blood samples analysed using Illumina 450K BeadChip arrays, were normalised using three different methods (with probe filtering undertaken pre- or post-normalisation). Batch effects were handled with a supervised algorithm, an unsupervised algorithm, or adjustment in the analysis model. Analysis was undertaken with and without adjustment for estimated cell type proportions. The effects estimated included intervention and BMI (effects of interest in the original study), infant sex and randomly assigned groups. Data processing and analysis methods were compared in relation to number and identity of differentially methylated probes, rankings of probes by p value and log-fold-change, and distributions of p values and log-fold-change estimates.

Results: There were differences corresponding to each of the processing and analysis choices. Importantly, some combinations of data processing choices resulted in a substantial number of spurious 'significant' findings. We recommend greater emphasis on replication and greater use of sensitivity analyses.

Clinical Trials Registration: ACTRN12607000161426

43

44

45 **Word Count:** 4647

46 Introduction and Background

47

48 With the advent of high-throughput assays, epigenome-wide DNA methylation studies have become
49 more popular, and researchers are now investigating the effects on DNA methylation (DNAm) of a wide
50 range of environmental exposures and physiological conditions, with particular interest in the
51 contribution of epigenetic mechanisms such as DNAm to the early life origins of health and disease. The
52 ability to perform EWAS is particularly useful in relation to conditions where associated differences in
53 DNAm are likely to be fairly modest (1). However, DNAm data – as with high-dimensional ‘omics’ data
54 generally – requires substantial pre-processing prior to analysis, including probe and sample filtering,
55 normalisation to remove variation due to technological factors, and correction for other factors which
56 may confound effects of interest, such as batch effects or differences in cell type proportions between
57 samples. Numerous methods exist to perform these processing steps, but there is no clear consensus on
58 the best processing or analysis approach (2,3).

59

60 We recently investigated the effect of an antenatal diet and lifestyle intervention, and of maternal early
61 pregnancy BMI, on neonatal cord blood DNA methylation in infants of mothers who were overweight or
62 obese in early pregnancy. The findings are reported in a companion paper. In brief, we did not find
63 evidence of differential methylation in relation to either the intervention or early pregnancy maternal
64 BMI, and were unable to replicate findings from previous studies which reported a range of loci to be
65 significantly differentially methylated in relation to these factors. Moreover, in conducting sensitivity
66 analyses involving use of different normalisation methods and methods for handling batch effects, we
67 observed a number of differences in results, both in relation to the most highly ranked probes and in the
68 ‘detection’ of effects which we believed to be spurious. We therefore set out to investigate the impact
69 of different data-processing choices in a more systematic way, looking at the effect of these choices on
70 detection of differentially methylated probes (DMPs), on overall distribution of p values and log-fold-
71 change (logFC) estimates, and on rankings of probes (by logFC and by p value).

72

73 In this paper we report the findings from a set of analyses conducted on data processed and handled
74 according to a combination of different prespecified choices. The particular factors we investigated
75 related to (a) filtering of probes before versus after normalisation; (b) method used for normalisation;
76 (c) method used to handle batch effects; and (d) adjustment vs non-adjustment for estimated cell type
77 proportions. We compared results from analyses estimating effects of the antenatal intervention and
78 maternal early pregnancy BMI, but also were interested in observing the behaviour of different data-
79 processing choices in relation to effects that were both known to be present, and known to be absent.
80 We therefore performed further analyses in which effects of infant sex, and of randomly assigned (fake)
81 groups were estimated.

82

83 Data and Methods

84 The LIMIT Randomised Controlled Trial

85

86 The LIMIT study was a randomised, controlled trial of an antenatal diet and lifestyle intervention for
87 women with early pregnancy BMI ≥ 25.0 kg/m². The study, and its primary and main secondary
88 outcomes, have been extensively reported elsewhere (4). Women were eligible if they had early
89 pregnancy BMI ≥ 25.0 kg/m², a singleton pregnancy between 10⁺⁰ and 20⁺⁰ weeks’ gestation, and no
90 previously existing diabetes. A total of 2212 women were randomised to receive either Lifestyle Advice
91 (n=1108), a comprehensive diet and lifestyle intervention, or Standard Care (n=1104), in which

92 antenatal care was delivered according to local guidelines (and did not include information on diet or
93 physical activity). The study was reviewed by the ethics committee of each participating instituting
94 including the Women's and Children's Health Network Human Research Ethics Committee (1839 &
95 2051); the Central and Northern Adelaide Health Network Human Research Ethics Committee (2008033)
96 and the Southern Adelaide Local Health Network Human Research Ethics Committee (128/08).
97 Informed written consent was obtained for all participants to participate in the LIMIT study, and
98 additional written consent was obtained to collect samples of umbilical cord blood at delivery for the
99 purposes of gene expression research related to weight and to the diet and lifestyle intervention.

100

101 The primary outcome of the LIMIT study was birth of a Large for Gestational Age (LGA) infant. There
102 were no significant differences observed between the groups in relation to this outcome; however, a
103 significantly lower incidence of birthweight >4kg was observed in the Lifestyle Advice group, with a
104 Relative Risk of 0.82 (95% CI: 0.68, 0.99, $p=0.04$). Additionally, measures of diet quality and physical
105 activity were improved in women in the Lifestyle Advice group compared to those in the Standard Care
106 group (5).

107

108 Cord Blood DNA for a range of secondary studies was collected at the time of birth from consenting
109 participants, and was frozen as whole blood preserved with EDTA. Funding was available to perform
110 DNA methylation analysis for a total of 649 samples, which were randomly selected from the total
111 number of available samples, balanced between the Lifestyle Advice and Standard Care groups. After
112 DNA extraction, genome-wide DNA methylation was performed using the Illumina Infinium
113 HumanMethylation 450K Bead-Chip array. Results were supplied as raw probe intensities (*idats* files).

114

115 For the additional analyses investigating known spurious effects, artificial (fake) groups were created by
116 assigning samples based on random draws from binomial distributions. The first grouping
117 ('Tortoiseshell' vs 'Tabby') was generated using a binomial distribution with 50% probability of
118 assignment to each group. The second grouping ('Long'- vs 'Short-Haired') was created to mimic
119 stratified randomisation as well as unequal proportions in each group: within each level of the first fake
120 group, samples were assigned to Long-Haired with 40% probability and Short-Haired with 60%
121 probability.

122

123 All data processing and analyses were undertaken using R version 4.0 (6).

124

125 Probe and Sample Filtering

126

127 The *minfi* package (7) was used to read in the raw *idats* files (without normalisation), and to calculate
128 both probe-wise and sample-wise 'detection p values'. Samples were identified as 'faulty' if they had a
129 detection p-value ≥ 0.05 ; 13 such samples were excluded; however these were due to a known chip
130 failure, and had subsequently been rerun. A further four samples were excluded because the correct
131 corresponding study identifier could not be ascertained, leaving 645 samples for analysis.

132

133 Probes were filtered using multiple criteria. Firstly, probes were excluded if they had a detection p-value
134 ≥ 0.001 in more than 25% of the 645 samples, indicating that their signal could not be accurately
135 detected for a large proportion of samples (8,9). Secondly, probes were excluded if they were on a list of
136 those previously identified as cross-reactive (10); i.e. there was a high probability they may hybridize to
137 locations on the genome different to those for which the probe was designed (8,11). Thirdly, probes
138 with an identified SNP within 3 nucleotides of the CpG site and minor allele frequency >1%, and probes

139 on the X and Y chromosomes were excluded. This was done in order to avoid spurious methylation
140 'differences' due either to SNPs within the CpG targets, or due to X and Y chromosomes (8,11). Filtering
141 of cross-reactive probes, probes with a nearby SNP, and probes on the X and Y chromosomes, was
142 performed using the *DMRCate* package (12). This left 426,572 probes available for analysis.

143

144 Probe filtering was performed either after normalisation (post-filtered) or prior to normalisation (pre-
145 filtered). The one exception for pre-filtering was when normalising using the BMIQ method, where
146 probes on the X and Y chromosome were retained as this was required in order for the function to run.

147

148

149 Normalisation

150

151 Normalisation involves making changes to the raw data in order to remove artifactual variation. In the
152 case of Illumina 450K BeadChip arrays, this requires correcting for the presence of two different probe
153 types. Infinium I probes use the same colour signal for methylated and unmethylated CpG and are often
154 used for regions of high CpG density, while Infinium II probes use different colours to differentiate
155 between methylated and unmethylated states (13,14). In general, the distribution of β values

156 $\left(\frac{M}{M + U + offset}\right)$ will be bimodal, with peaks corresponding to methylated and unmethylated states), but
157 the distribution of Infinium II probes differs from that of Infinium I, being more compressed towards 0.5
158 (13) and hence having a smaller 'dynamic range' (8,15).

159

160 Numerous different methods exist for normalising Illumina BeadChip array data, but there is little
161 consensus or guidance on which should be employed in a given context. The main advice is that
162 'between-array' methods, which normalise across samples, are preferable when global differences
163 between samples are expected, while 'within-array' methods, which normalise probes within each
164 sample, are better suited to effects in which the majority of genes will not be differentially expressed.
165 (9) The latter is the context in which many EWAS studies, including the present one, are conducted; as
166 noted above, only modest differences in a small proportion of genes are expected for most early-life
167 exposures. The methods chosen for the present investigation have all been used in the context of
168 studies such as this: Categorical-Subset Quantile Normalisation (SQN) (14,16), Beta-Mixture Quantile
169 Normalisation (BMIQ) (15), and Subset-Quantile Within-Array Normalisation (SWAN) (18). While
170 numerous other methods exist, a comparison of all available normalisation methods was beyond the
171 scope of this paper. Further details on the methods are given in the Supplementary Information.

172

173 Both Subset Quantile Normalisation and Subset-Within-Array-Normalisation were performed using
174 functions in the *minfi* package (*preprocessQuantile* and *preprocessSWAN* respectively), on raw intensity
175 data. Beta-Mixture Quantile normalisation was performed using the *champ.norm* function in the *ChAMP*
176 package after converting intensities to β values.

177

178 Batch Effects

179

180 Batch effects arise when samples are processed in separate groups, creating unwanted variation due,
181 for example, to different reagents, different plates or different scanner settings. (3,19,20)

182 There are 12 Illumina 450K arrays (samples) per chip (this is reduced to 8 arrays per chip for the more
183 recent 850K array); thus most studies involving large numbers of samples must be run on multiple chips.

184 This introduces extra variability to the data, and may also confound the actual effects of interest, if

185 samples from different groups are not evenly distributed between the batches. These effects must be
186 accounted for in order to obtain valid estimates of the effects of interest.

187

188 Unlike probe filtering and normalisation, batch effects can be handled at the analysis stage, by adjusting
189 for batch in the analysis model. However, it is also common to address batch effects at the data-
190 processing stage, using a batch-correction algorithm, with the resulting data considered to be free of
191 batch effects (19). The ComBat algorithm has been widely used and considered the most effective
192 method (2) of removing batch effects in DNAm data; it has been incorporated into various analysis
193 pipelines. Until recently, ComBat could be implemented only as a supervised method, in which the
194 biological factors of interest had to be specified along with the batch variable (3) (21); it can now also be
195 implemented as an unsupervised method, in which only the batch variable is specified.

196

197 For each of the normalised datasets (i.e. SQN, BMIQ and SWAN normalised datasets, each with probes
198 filtered either before or after normalisation), we handled batch effects in three ways: firstly, by
199 adjusting for batch in the analysis model (BatchAdjust); secondly, implementing the supervised ComBat
200 algorithm (sCB); and thirdly, implementing the unsupervised ComBat algorithm (uCB). For the
201 supervised ComBat algorithm, it was necessary to run the process twice: once with the effects of
202 interest specified as maternal early pregnancy BMI, antenatal intervention group, and their interaction;
203 and again with the effects of interest specified as Fake Group 1, Fake Group 2, their interaction, and
204 infant sex.

205

206 Cell Type Proportions

207 Cord blood, like whole blood, contains a mixture of different cell types, which have different DNA
208 methylation profiles.(22,23) If samples differ in the proportion of these different cell types, this may
209 confound effects of interest, either hiding true differences in DNAm, or giving rise to spurious
210 differences. Most studies of the effect of BMI, lifestyle interventions, or similar factors on cord blood
211 DNA methylation have not attempted (or have not documented an attempt) to correct for potential
212 differences in cell type composition, perhaps because reference profiles for cord blood were not
213 available until more recently (24), and the mix of cell types and DNAm profiles may differ in cord blood
214 compared to whole blood, making it inappropriate to apply reference profiles from whole blood to cord
215 blood data.(25)

216

217 We estimated the proportion of B cells, CD4+T, CD8+T, granulocytes, monocytes, natural killer, and
218 nucleated RBCs in the raw data using the *estimateCellCounts()* function in the *minfi* package, with the
219 Cord Blood reference panel. The estimated proportions were then added to the metadata for use as
220 adjustment variables in the analyses. We then undertook analyses either adjusted or not adjusted for
221 estimated cell type proportion.

222

223 Figure 1 depicts the combinations of data-processing and analysis choices that were undertaken. In
224 brief, there were six normalised datasets (three different normalisation methods, with probe filtering
225 performed before normalisation or after normalisation). These datasets were either used immediately
226 for analysis, or processed using the ComBat algorithm (in both supervised and unsupervised form) prior
227 to analysis. Non-ComBat-processed data were analysed with three different models: an unadjusted
228 model (containing only the effects of interest), a model adjusted for batch, and a model adjusted for
229 batch and estimated cell type proportions. ComBat-processed data were analysed with two different
230 models: one containing no other adjustment variables (but assumed to be 'pre-adjusted' for batch), and
231 one adjusted for cell type proportion.

232

233 Statistical Analysis

234

235 Differential methylation was investigated probe-wise using linear models with empirical Bayes variance
236 correction as implemented in the *limma* package (26,27). For effects of BMI and intervention, models
237 specified BMI (as continuous and mean-centred), intervention (Lifestyle Advice vs Standard Care), and
238 their interaction. Contrasts were specified for the effect of the intervention at the mean BMI of the
239 cohort, and at 5 kg/m² above the mean; and for the effect of an increase of 5 kg/m² in BMI in each of the
240 intervention groups (Standard Care, Lifestyle Advice). For effects of fake groups and infant sex, the
241 models specified sex (Female vs Male), Fake Group 1 (Tortoiseshell vs Tabby), Fake Group 2 (Long-
242 Haired vs Short-Haired), and their interaction. Contrasts were specified for infant sex, and for the effect
243 of each fake group separately within levels of the other fake group (i.e. effect of Tortoiseshell in Long-
244 Haired and in Short-Haired; and effect of Short-Haired in Tortoiseshell and Tabby).

245

246 For each contrast in each model, the number and identity (where applicable) of any differentially
247 methylated probes (DMPs) were obtained. For detection of DMPs, *limma*'s default method of multiple-
248 comparisons correction (Benjamini-Hochberg) was used; this method controls the False Discovery Rate,
249 or the proportion of statistically significant results not corresponding to true effects. Where DMPs were
250 obtained, a comparison was made using the Holm method, which controls the Family-Wise-Error Rate
251 (the probability that at least one statistically significant result does not correspond to a true effect). The
252 full set of p values and estimated log-fold-changes (for all 426572 probes) corresponding to each
253 contrast were also obtained, in order to compare probe rankings and overall distributions. To make the
254 comparison more tractable, probe rankings were investigated using only those probes ranked in the top
255 10 (i.e. the probes with the smallest p value, or largest estimated logFC, in a given model).

256

257 The findings from different data-processing choices were then compared along five dimensions:

- 258 1. Number and identity of differentially methylated probes (DMPs); for infant sex, the direction of
259 differential methylation ('down', corresponding to negative t-statistics or lower methylation in
260 females, versus 'up', corresponding to higher methylation in females) was also examined.
- 261 2. Consistency of rankings by p value for 'top 10' probes;
- 262 3. Consistency of rankings by logFC for 'top 10' probes, as well as the consistency of the logFC
263 estimates;
- 264 4. Overall distribution of p values;
- 265 5. Overall distribution of logFC estimates.

266

267 Results

268 All data processing choices had an impact on downstream analysis results, in terms of the number (and
269 identity) of differentially methylated probes, rankings of probes (by p value and logFC), estimates of
270 logFC, and overall distribution of p values and logFC, corresponding to both real and spurious effects of
271 interest. In some cases a consistent impact of a particular choice was observed, while in others there
272 was no consistent pattern, or this pattern varied according to the other choices with which it was
273 combined.

274

275 Tables 1-3 give information about differentially methylated probes in each of the models fitted for the
276 combinations of filtering, normalisation, batch correction and cell adjustment approaches. Table 1 lists
277 the number of significant negative ('down') probes and significant positive ('up') probes for infant sex.

278 Table 2 gives the number of differentially methylated probes for any of the BMI and intervention effects,
279 while Table 3 gives the number of differentially methylated probes for any of the fake group effects (the
280 specific effects and probes, as well as their rankings in other models, are listed in Supplementary Tables
281 3-8).

282

283 Differences in ranking of probes by p value and log-Fold-Change are shown in Figures 2 and 3,
284 respectively, for a selected set of effects (infant sex; the effect of maternal BMI in the Standard Care
285 group, and the effect of 'short-haired' in 'Tabby'). Similarly, the overall distribution of p values and of
286 log-Fold-Change estimates for this same set of selected effects is shown in Figures 4 and 5.

287

288 Effect of probe filtering pre-normalisation vs post-normalisation

289 Filtering probes prior to normalisation, compared to filtering after normalisation, led to modest
290 differences in number of DMPs, rankings of probes by logFC and p value, and overall distributions of p
291 values and logFC estimates. Filtering pre-normalisation produced different numbers of DMPs for infant
292 sex, but the nature of the effect differed by normalisation method: in SWAN data there was a consistent
293 pattern of fewer significant probes both negative and positive, while in BMIQ data there were fewer
294 negative but more positive probes, and in SQN data there were more negative but fewer positive
295 probes. In relation to effects of BMI, intervention, and fake groups, differences were harder to discern
296 due to the lack of any DMPs for many models; however, when DMPs were present for an effect, there
297 was a tendency for there to be a greater number of them in the pre-filtered data.

298

299 Probe rankings, by logFC and p value, tended to be relatively consistent between pre-filtered and post-
300 filtered data, with some cases of larger discrepancies in rankings for individual probes. The discrepancies
301 were more common, and larger, for fake group, BMI and intervention effects than for infant sex.
302 Similarly, there were no dramatic differences in distributions of p values or logFC estimates for infant
303 sex; there were differences in distribution between pre- and post-filtered data for fake group,
304 intervention and BMI effects, but there was no consistent pattern to these differences.

305

306 Effect of Normalisation Method

307 Normalisation method had a substantial influence on number and identity of DMPs, rankings of probes
308 and p values, and distributions of p values and logFC estimates. For infant sex, SQN data consistently
309 had the highest number of significant negative probes and the lowest number of significant positive
310 probes, while SWAN data always had the lowest number of significant positive probes. For BMI and
311 intervention effects, only BMIQ data produced DMPs where no ComBat processing was used; in data
312 processed using supervised ComBat, all three normalisation methods resulted in some DMPs, but the
313 number and identity of these probes differed. In fake group data, SQN data produced a large number of
314 significant probes in non-ComBat-processed and supervised-ComBat data, while BMIQ and SWAN data
315 produced a small number of probes in supervised-ComBat data only; again, the number and identity of
316 the probes differed between the normalisation methods.

317

318 There was a fair degree of consistency in rankings of probes by p value for infant sex, but some large
319 discrepancies in rankings for BMI, intervention, and fake group effects. The rankings were less
320 consistent for highest-ranked probes by logFC, with some quite large differences in both rankings and
321 effect estimates (including different directions of effect) for infant sex, BMI, intervention and fake
322 groups. BMIQ estimates tended to be more extreme (further from 0) than the other two methods.

323

324 Distributions of p values and logFC estimates also differed between normalisation methods. For p
325 values the differences were not consistent across models and effects, but for logFC there was a clear
326 difference between BMIQ and the other two methods, with the range of estimates in BMIQ data being
327 much more widely dispersed; SQN and SWAN data had more similar distributions, but SQN was
328 moderately narrower than SWAN across all effects and models.

329

330 Effect of Batch Correction Method

331 There were clear differences in all dimensions between batch correction methods. For all effects (infant
332 sex, BMI, intervention and fake groups), supervised ComBat processing produced a larger number of
333 DMPs compared to either unsupervised ComBat processing or adjustment for batch in the analysis
334 model. The difference between unsupervised ComBat and batch-adjustment was less consistent for
335 infant sex effects, but for BMI, intervention and fake group effects, there were no DMPs in unsupervised
336 ComBat models, whereas there were a few for batch-adjusted models.

337

338 Rankings of top probes by p value were relatively consistent between batch-adjustment methods for
339 infant sex, but there were some large discrepancies particularly for BMI and intervention effects, and
340 especially in BMIQ data. The same phenomenon was observed for logFC rankings, which also showed a
341 tendency for logFC estimates in unsupervised-ComBat data to be smaller in absolute magnitude (closer
342 to 0).

343

344 The distribution of p values showed clear and consistent differences between batch-correction methods,
345 with the distribution in supervised ComBat data shifted down substantially relative to both unsupervised
346 ComBat and batch-adjusted models, for all effects. For logFC estimates, supervised ComBat and batch-
347 adjusted data were generally fairly similar, but unsupervised ComBat data generally resulted in a
348 narrower range.

349

350 Effect of Adjustment for Estimated Cell Type Proportion

351 Adjustment for cell type proportion produced different results, but the impact differed depending on
352 the effect. Adjustment for batch resulted in a substantially larger number of DMPs (both negative and
353 positive) for infant sex, but reduced the number of DMPs for fake groups (for models where there were
354 DMPs for fake groups effects). For BMI and intervention, the effect of cell type adjustment was mostly
355 but not entirely to produce more DMPs.

356

357 The effect of cell type adjustment on top probe rankings was fairly modest, although some quite large
358 discrepancies were observed for p value rankings, logFC rankings, and logFC estimates. The effect on
359 distribution of p values depended on the effect: for infant sex, adjustment for cell type proportion
360 consistently (for all normalisation and batch-correction methods) shifted the distribution downwards,
361 whereas the differences were less consistent and smaller in BMI, intervention and fake group effects.
362 There were no large or consistent differences in distribution of logFC estimates between cell-type-
363 adjusted and non-adjusted models.

364

365 Discussion

366 Different choices in probe filtering, normalisation, batch handling, and adjustment for cell types resulted
367 in different findings regarding the presence and identity of differentially methylated probes, rankings of
368 probes by p value and log-fold-change, and different overall distributions of p values and log-fold-
369 change estimates. Some differences were relatively modest, while others were more substantial. The

370 effect of some choices appeared to be consistent: in particular, supervised ComBat processing resulted
371 in more differentially methylated probes and shifted the distribution of p values downward, while
372 unsupervised ComBat processing resulted in a narrower range of log-fold-change estimates which were
373 generally closer to 0 (a null effect) than other methods. Data normalised using BMIQ tended to produce
374 a more widely-dispersed distribution of log-fold-change estimates and also appeared to respond in a
375 more volatile manner to other data processing choices. By contrast, the effect of filtering probes prior
376 to normalisation, and of adjustment for estimated cell type proportion, had different impacts depending
377 on other data processing choices, and the effects being studied. Of interest, the number of differentially
378 methylated probes for infant sex was increased, and the p value distribution shifted downward, when
379 models were adjusted for estimated cell type proportion, suggesting that the removal of noise due to
380 cell type differences allowed more precise estimation of these effects. However, the effect in relation to
381 fake group effects was equivocal.

382
383 The results of these analyses are consistent with other investigations which have been undertaken into
384 different data-processing and analysis choices. In particular, the potential for ‘false positives’ to result
385 from supervised batch-correction methods specifying effects of interest has been previously identified
386 by a number of authors.(2,3,19). The finding that the distribution of p values in the supervised ComBat
387 algorithm tends to shift the p value distribution downward is consistent with the finding of Nygaard et al
388 that, in contexts where the effects of interest are not evenly spread between batches, the distribution of
389 F-statistics will be biased upwards (19). While implementation as an unsupervised method may be
390 preferable, our findings suggest that this may create a different problem, with the estimates of log-fold-
391 change corresponding to effects of interest biased towards zero.

392
393 In terms of different normalisation approaches, Wu et al (17) compared a variety of normalisation
394 approaches, including GenomeStudio, SWAN, BMIQ, and a ‘complete pipeline’ incorporating SQN, when
395 investigating the association between smoking and cord blood methylation. They found that with more
396 stringent Type I error control, and for the “most confident” results, the different normalisation methods
397 gave similar values; more differences arose with laxer Type I error control. When using a split-data
398 method to validate findings, many “significant” differences at the CpG level in the development data did
399 not validate in the testing data. They noted a tendency for more statistically significant differences to
400 arise in SQN data, which they hypothesise may be due to reduced overall variance. In our investigation,
401 the main context in which SQN data produced a large number of spurious differentially methylated
402 probes was when supervised ComBat, or adjustment for batch in the model, was used. This suggests
403 that batch adjustment is particularly ill-advised in the context of SQN normalisation; since SQN involves
404 between-array as well as within-array normalisation, additional adjustment for batch may be over-
405 correcting.

406
407 Our findings do not suggest that there is one particular combination of methods which can be
408 guaranteed to ‘work’ in all contexts, although there are some recommendations which can be made.
409 Echoing Nygaard et al, we suggest that adjustment for batch in the model, rather than batch-correction
410 algorithms, be used. Secondly, as many other authors have noted, researchers working with DNAm data
411 should better understand the methods built into standard pipelines (2,3), and should better document
412 the specific data-processing methods used (2,19). The use of a more stringent method of Type I error
413 control may also help to reduce the number of spurious findings: the use of FDR correction methods
414 such as Benjamini-Hochberg, while very common (9), may not be sufficient to deal with higher rates of
415 spurious results (19). In our data, the use of the Holm method (which controls the Family-Wise Error
416 Rate) reduced, but did not eliminate, spurious findings associated with fake group effects. Investigation

417 of DNA regions, rather than probe-wise analysis, may also help to differentiate true methylation
418 differences from spurious ones (14).

419

420 It is also important, in our view, to pay more attention to the context in which a particular epigenome-
421 wide analysis is performed. For example, a less stringent method of Type I error control may often be
422 chosen because the study is exploratory (hypothesis-generating) rather than confirmatory, and it is
423 considered more important not to miss potential findings than to rule out spurious ones. In this case,
424 the results from such studies should be interpreted accordingly: as suggestive findings which cannot be
425 confidently accepted until they are validated in new data. The validation of existing findings should be
426 treated as a high priority in epigenetics research (3).The degree of confidence that can be placed in any
427 new discoveries could be enhanced by performing sensitivity analyses – re-performing analyses using
428 different normalisation methods, batch correction methods, or models - which we believe should
429 become standard in this area.

430 **References**

431

- 432 1. Marabita F, Almgren M, Lindholm ME, Ruhrmann S, Fagerström-Billai F, Jagodic M, et al. An
433 evaluation of analysis pipelines for DNA methylation profiling using the Illumina
434 HumanMethylation450 BeadChip platform. *Epigenetics*. 2013 Mar 1;8(3):333–46.
- 435 2. Zindler T, Frieling H, Neyazi A, Bleich S, Friedel E. Simulating ComBat: how batch correction can
436 lead to the systematic introduction of false positive results in DNA methylation microarray studies.
437 *BMC Bioinformatics*. 2020 Jun 30;21(1):271.
- 438 3. Price EM, Robinson WP. Adjusting for Batch Effects in DNA Methylation Microarray Data, a Lesson
439 Learned. *Front Genet* [Internet]. 2018 Mar 16 [cited 2020 Sep 14];9. Available from:
440 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864890/>
- 441 4. Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN, et al. Antenatal lifestyle
442 advice for women who are overweight or obese: LIMIT randomised trial. *BMJ*. 2014 Feb
443 10;348(feb10 3):g1285–g1285.
- 444 5. Dodd JM, Cramp C, Sui Z, Yelland LN, Deussen AR, Grivell RM, et al. The effects of antenatal dietary
445 and lifestyle advice for women who are overweight or obese on maternal diet and physical
446 activity: the LIMIT randomised trial. *BMC Med*. 2014 Oct 13;12(1):161.
- 447 6. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria:
448 R Foundation for Statistical Computing; 2018 [cited 2020 Sep 2]. Available from: [https://www.r-](https://www.r-project.org/)
449 [project.org/](https://www.r-project.org/)
- 450 7. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible
451 and comprehensive Bioconductor package for the analysis of Infinium DNA methylation
452 microarrays. *Bioinformatics*. 2014 May 15;30(10):1363–9.
- 453 8. Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. A comprehensive overview
454 of Infinium HumanMethylation450 data processing. *Brief Bioinform*. 2014;15(6):929–41.
- 455 9. Maksimovic J, Phipson B, Oshlack A. A cross-package Bioconductor workflow for analysing
456 methylation array data. *F1000Research*. 2017 Apr 5;5:1281.
- 457 10. Chen Y, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al. Discovery of cross-
458 reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray.
459 *Epigenetics*. 2013 Feb;8(2):203–9.
- 460 11. Naeem H, Wong NC, Chatterton Z, Hong MKH, Pedersen JS, Corcoran NM, et al. Reducing the risk
461 of false discovery enabling identification of biologically significant genome-wide methylation status
462 using the HumanMethylation450 array. *BMC Genomics*. 2014;15(1):51.
- 463 12. Peters TJ, Buckley MJ, Statham AL, Pidsley R, Samaras K, V Lord R, et al. De novo identification of
464 differentially methylated regions in the human genome. *Epigenetics Chromatin*. 2015 Jan
465 27;8(1):6.

- 466 13. Pidsley R, CC YW, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven approach to preprocessing
467 Illumina 450K methylation array data. *BMC Genomics*. 2013;14:293–293.
- 468 14. Wang T, Guan W, Lin J, Boutaoui N, Canino G, Luo J, et al. A systematic study of normalization
469 methods for Infinium 450K methylation data using whole-genome bisulfite sequencing data.
470 *Epigenetics*. 2015;10(7):662–9.
- 471 15. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, et al. A beta-
472 mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k
473 DNA methylation data. *Bioinformatics*. 2013 Jan 15;29(2):189–96.
- 474 16. Wu MC, Joubert BR, Kuan P, Håberg SE, Nystad W, Peddada SD, et al. A systematic assessment of
475 normalization approaches for the Infinium 450K methylation platform. *Epigenetics*. 2014 Feb
476 1;9(2):318–29.
- 477 17. Hicks SC, Irizarry RA. *quantro*: a data-driven approach to guide the choice of an appropriate
478 normalization method. *Genome Biol*. 2015 Dec;16(1):117.
- 479 18. Maksimovic J, Gordon L, Oshlack A. SWAN: Subset-quantile Within Array Normalization for Illumina
480 Infinium HumanMethylation450 BeadChips. *Genome Biol*. 2012 Jun 15;13(6):R44.
- 481 19. Nygaard V, Rødland EA, Hovig E. Methods that remove batch effects while retaining group
482 differences may lead to exaggerated confidence in downstream analyses. *Biostatistics*. 2016 Jan
483 1;17(1):29–39.
- 484 20. Morris TJ, Beck S. Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip
485 (450k) data. *Methods*. 2015;72(C):3–8.
- 486 21. Fortin J-P, Triche T, Hansen K. Preprocessing, normalization and integration of the Illumina
487 HumanMethylationEPIC array. 2016 Jul 23 [cited 2018 Jun 21]; Available from:
488 <http://biorxiv.org/lookup/doi/10.1101/065490>
- 489 22. Jaffe AE, Irizarry RA. Accounting for cellular heterogeneity is critical in epigenome-wide association
490 studies. *Genome Biol*. 2014;15(2):R31–R31.
- 491 23. Teschendorff AE, Zheng SC. Cell-type deconvolution in epigenome-wide association studies: a
492 review and recommendations. *Epigenomics*. 2017 May;9(5):757–68.
- 493 24. Bakulski KM, Feinberg JL, Andrews SV, Yang J, Brown S, L McKenney S, et al. DNA methylation of
494 cord blood cell types: Applications for mixed cell birth studies. *Epigenetics*. 2016 May 3;11(5):354–
495 62.
- 496 25. Cardenas A, Allard C, Doyon M, Houseman EA, Bakulski KM, Perron P, et al. Validation of a DNA
497 methylation reference panel for the estimation of nucleated cells types in cord blood. *Epigenetics*.
498 2016 Nov;11(11):773–9.
- 499 26. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. *limma* powers differential expression
500 analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015;43(7):e47–e47.

501 27. Smyth GK. limma: Linear Models for Microarray Data. *Bioinforma Comput Biol Solut Using R*
502 *Bioconductor*. (2005):397–420.

503

504

Figure 1

Flowchart of Data Processing and Analysis

Figure 1 Flowchart of Data Processing and Analysis




Figure 3(on next page)


Probes ranked in top 10 in any Batch and Cell-Adjusted Model by Log Fold Change, for (a) Infant Sex, (b) BMI in Standard Care, (c) Short-Haired in Tabby.

Only models from data with probe filtered post-normalisation are included, to simplify results presentation. The model is one adjusting for batch (either explicitly in the model or via batch-correction algorithm) and cell type proportion. The graphs give the estimated log-Fold-Change (circles) and 95% confidence interval by normalisation method and batch-correction method, with rank also indicated by the size of the circles.


Figure 3 Probes Ranked in Top 10 in any Batch and Cell-Adjusted Model by Log Fold Change, for (a) Infant Sex, (b) BMI in Standard Care, (c) Short-Haired in Tabby.

Only models from data with probe filtered post-normalisation are included, to simplify results presentation. The model is one adjusting for batch (either explicitly in the model or via batch-correction algorithm) and cell type proportion. The graphs give the estimated log-Fold-Change (circles) and 95% confidence interval by normalisation method and batch-correction method, with rank also indicated by the size of the circles.

(a) Infant Sex



(b) BMI in Standard Care



(c) Short-Haired in Tabby




Figure 4

Distribution of Unadjusted P Values by Normalisation and Batch Correction Method, for Batch and Cell Adjusted Models

Only models from data where probe filtering was performed post-normalisation are included. The model is one adjusting for batch (either explicitly in the model or via batch-correction algorithm) and cell type proportion.

Figure 4 Distribution of Unadjusted P Values by Normalisation and Batch Correction Method, for Batch and Cell Adjusted Models
Only models from data where probe filtering was performed post-normalisation are included. The model is one adjusting for batch (either explicitly in the model or via batch-correction algorithm) and cell type proportion.




Figure 5

Distribution of Log-Fold-Change Estimates by Normalisation and Batch Correction Method, for Batch and Cell Adjusted Models

Only models from data where probe filtering was performed post-normalisation are included. The model is one adjusting for batch (either explicitly in the model or via batch-correction algorithm) and cell type proportion.

Figure 5 Distribution of Log-Fold-Change Estimates by Normalisation and Batch Correction Method, for Batch and Cell Adjusted Models
Only models from data where probe filtering was performed post-normalisation are included. The model is one adjusting for batch (either explicitly in the model or via batch-correction algorithm) and cell type proportion.




Table 1 (on next page)

Number of DMPs for Infant Sex (Female), by Probe Filtering Method, Batch Correction Method, Normalisation Method and Cell Type Method

* No adjustment beyond the correction for batch as implemented in the ComBat algorithm

1 **Table 1. Number of DMPs for Infant Sex (Female), by Probe Filtering Method, Batch Correction Method, Normalisation Method and Cell Type**
 2 **Method**
 3

Model		SQN		BMIQ		SWAN	
		Post Filtered	Pre Filtered	Post Filtered	Pre Filtered	Post Filtered	Pre Filtered
No ComBat							
- Unadjusted	Down	15088	14878	7935	7554	7581	6890
	Up	20587	20441	28004	30741	25784	25962
- Adjusted for Batch	Down	13132	13215	6602	6112	7100	6140
	Up	20225	19956	39482	34408	30362	29780
- Adjusted for Batch + Cell	Down	28406	28633	15855	14900	14239	10408
	Up	31973	32204	39719	45255	43155	40709
Supervised ComBat							
- Unadjusted*	Down	20967	21230	11235	10180	10772	9252
	Up	25690	25320	41518	48191	45193	43237
- Adjusted for Cell	Down	35559	36022	18036	16512	16423	12198
	Up	37068	36972	56521	64851	68769	65109
UnSupervised ComBat							
- Unadjusted*	Down	14603	14763	7634	6836	7344	6377
	Up	21336	21041	30961	34882	31892	31170
- Adjusted for Cell	Down	28012	28286	14060	12916	13030	9560
	Up	32478	32447	43370	49520	52037	49102

4 * No adjustment beyond the correction for batch as implemented in the ComBat algorithm
 5

Table 2 (on next page)

DMPs for Intervention and BMI Effects

1 **Table 2 DMPs for Intervention and BMI Effects**

2

Model	SQN		BMIQ		SWAN	
	Post Filtered	Pre Filtered	Post Filtered	Pre Filtered	Post Filtered	Pre Filtered
No ComBat						
- Unadjusted	0	0	7	11	0	0
- Adjusted for Batch	0	0	8	6	0	0
- Adjusted for Batch + Cell	0	0	6	8	0	0
Supervised ComBat						
- Unadjusted	1	1	0	99	0	0
- Adjusted for Cell	3	3	9	208	6	6
UnSupervised ComBat						
- Unadjusted	0	0	0	0	0	0
- Adjusted for Cell	0	0	0	0	0	0

3

Table 3 (on next page)

DMPs for Fake Groups

1 **Table 3 DMPs for Fake Groups**

2

	SQN		BMIQ		SWAN	
Model	Post Filtered	Pre Filtered	Post Filtered	Pre Filtered	Post Filtered	Pre Filtered
No ComBat						
- Unadjusted	0	0	0	0	0	0
- Adjusted for Batch	2180	2574	0	0	0	0
- Adjusted for Batch + Cell	0	0	0	0	0	0
Supervised ComBat						
- Unadjusted	6768	7007	3	6	8	8
- Adjusted for Cell	124	134	1	2	0	0
UnSupervised ComBat						
- Unadjusted	0	0	0	0	0	0
- Adjusted for Cell	0	0	0	0	0	0

3